Bevacizumab, ranibizumab, and sorafenib are among the most widely used vascular endothelial growth factor (VEGF) signaling antagonists that inhibit tumor vasculatures and abnormal vessel growth in patients with macular degeneration or proliferative diabetic retinopathy3–5. The gene discussed is VEGFA; the disease is neoplasm.